摘要
目的探讨乳腺癌骨转移患者外泌体miR-21、miR-184表达情况及其与骨转移的关系。方法乳腺癌患者110例为乳腺癌组,乳腺良性肿块患者80例为良性组,体检健康者100例为对照组,比较3组外泌体miR-21、miR-184相对表达量。乳腺癌组根据随访期间是否发生骨转移分为骨转移组50例和非骨转移组60例,比较骨转移组和非骨转移组外泌体miR-21、miR-184相对表达量及不同骨痛程度和转移分级患者外泌体miR-21、miR-184相对表达量。采用Pearson相关分析乳腺癌骨转移患者外泌体miR-21与miR-184相对表达量的相关性,采用多因素logistic回归分析外泌体miR-21、miR-184相对表达量对乳腺癌患者发生骨转移的影响;绘制ROC曲线,评估外泌体miR-21、miR-184相对表达量对乳腺癌患者发生骨转移的预测价值。结果乳腺癌组患者外泌体miR-21、miR-184相对表达量(2.02±1.17、1.17±0.03)高于良性组(0.31±0.05、0.04±0.02)和对照组(0.30±0.04、0.04±0.01)(P<0.05),良性组与对照组比较差异无统计学意义(P>0.05)。骨转移组外泌体miR-21、miR-184相对表达量(3.04±0.52、1.69±0.31)高于非骨转移组(1.17±0.41、0.74±0.22)(P<0.05),且随骨痛程度加重、骨转移分级升高外泌体miR-21、miR-184相对表达量升高(P<0.05);乳腺癌骨转移患者外泌体miR-21与miR-184相对表达量呈正相关(r=0.940,P<0.001);外泌体miR-21、miR-184相对表达量增高是乳腺癌患者发生骨转移的影响因素(OR=9.995,95%CI:3.513~28.434,P<0.001;OR=8.215,95%CI:2.436~27.699,P=0.001);外泌体miR-21、miR-184相对表达量最佳截断值为2.540、1.565时,预测乳腺癌患者发生骨转移的AUC分别为0.878(95%CI:0.808~0.947,P<0.001)、0.861(95%CI:0.761~0.918,P<0.001),灵敏度分别为98.30%、86.70%,特异度分别为74.80%、76.00%。结论外泌体miR-21、miR-184可能参与了乳腺癌患者骨转移的发生与发展,二者在乳腺癌骨转移患者中表达呈正相关,早期检测对乳腺癌患者骨转移有一定预测价值。
Objective To investigate the expressions of miR-21 and miR-184 in breast cancer patients with bone metastasis and the relationships with bone metastasis. Methods The relative expressions of miR-21 and miR-184 were detected in 110 patients with breast cancer(breast cancer group), 80 patients with benign lesions(benign group), and 100 healthy volunteers(control group). Breast cancer group was redivided into bone metastasis group(n=50) and non-metastasis group(n=60) to compare the relative expressions of miR-21 and miR-184 between two groups, and in patients with different bone pain degrees and metastasis grades. Pearson correlation was used to analyze the correlation between the relative expression levels of miR-21 and miR-184 in breast cancer patients with bone metastasis. Multivariate logistic regression analysis was used to study the influence of relative expressions of miR-21 and miR-184 on bone metastasis in breast cancer patients. ROC curve was drawn to evaluate the values of the relative expressions of miR-21 and miR-184 to predicting bone metastasis in breast cancer patients. Results The relative expressions of miR-21 and miR-184 were higher in breast cancer group(2.02±1.17,1.17±0.03)than those in benign group(0.31±0.05,0.04±0.02)and control group(0.30±0.04,0.04±0.01)(P<0.05),and showed no significant differences between benign group and control group(P>0.05).The relative expressions of miR-21 and miR-184 were higher in bone metastasis group(3.04±0.52,1.69±0.31)than those in non-metastasis group(1.17±0.41,0.74±0.22)(P<0.05),and were in an increasing tendency with the aggravation of bone pain and the increase of bone metastasis grade(P<0.05).The relative expression of miR-21 was positively correlated with the relative expression of miR-184 in breast cancer patients with bone metastasis(r=0.940,P<0.001).The high relative expressions of miR-21 and miR-184 were the influencing factors for bone metastasis in breast cancer patients(OR=9.995,95%CI:3.513-28.434,P<0.001;OR=8.215,95%CI:2.436-27.699,P=0.001).When the optimal cut-off values of the relative expressions of miR-21 and miR-184 were2.540 and 1.565,the AUCs for predicting bone metastasis in breast cancer patients were 0.878(95%CI:0.808-0.947,P<0.001)and 0.861(95%CI:0.761-0.918,P<0.001),the sensitivities were 98.30% and 86.70%,and the specificities were 74.80% and 76.00%,respectively.Conclusion miR-21 and miR-184 might be involved in the occurrence and development of bone metastasis in breast cancer patients.miR-21 is positively correlated with miR-184 in breast cancer patients with bone metastasis,and early detection of them two has certain predictive value for bone metastasis.
作者
刘柳
张娜贤
李刚
杨明
姬玉涵
刘丽娜
尹先哲
LIU Liu;ZHANG Naxian;LI Gang;YANG Ming;JI Yuhan;LIU Lina;YIN Xianzhe(Department of Breast Cancer,the Second People’s Hospital of Nanyang,Nanyang 473000,China;Department of Oncology,the Second People’s Hospital of Nanyang,Nanyang 473000,China)
出处
《中华实用诊断与治疗杂志》
2020年第8期763-767,共5页
Journal of Chinese Practical Diagnosis and Therapy
基金
河南省医学科技攻关计划项目(201602378)。
